Ledger. Australian venture funding, tracked

Company

M:M Bio Pty Ltd

Coverage

Stories naming M:M Bio Pty Ltd. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Funding announcement

Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers

Pathios Therapeutics has begun treating patients in an Australian Phase 1/2 trial of its GPR65 inhibitor PTT-4256 for advanced solid tumours. Backers to date include Canaan, Brandon Capital and Bristol Myers Squibb.

Brandon BioCatalyst portfolio 21 Nov 2024 Brandon CapitalBristol-Myers SquibbCanaanGrey Wolf TherapeuticsM:M Bio Pty LtdPathios TherapeuticsThirtyFiveBioVida Strategic PartnersPaul G. HighamTim BronsDr Tom McCarthy
Funding announcement

Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers

Pathios Therapeutics has dosed the first patient in a Phase 1/2 trial of its GPR65 inhibitor PTT-4256, run by its Australian team; the company also cites US$58M raised to date.

Brandon Capital portfolio 21 Nov 2024 Brandon CapitalBristol-Myers SquibbCanaanGrey Wolf TherapeuticsM:M Bio Pty LtdMolecule to Medicine (MTM)Pathios TherapeuticsThirtyFiveBioVida Strategic PartnersPaul G. HighamTim BronsDr Tom McCarthy

Something wrong? Tell us